Goldman Sachs Group Inc. started coverage on shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research note published on Friday. The brokerage issued a buy rating and a $189.00 target price on the biopharmaceutical company’s stock.

GWPH has been the subject of several other research reports. Morgan Stanley reissued a buy rating and set a $149.00 price target on shares of GW Pharmaceuticals PLC in a report on Friday, June 10th. Leerink Swann reissued a buy rating and set a $130.00 price target on shares of GW Pharmaceuticals PLC in a report on Tuesday, June 21st. Janney Montgomery Scott initiated coverage on shares of GW Pharmaceuticals PLC in a report on Monday, June 27th. They set a sell rating and a $40.00 price target for the company. Cowen and Company reissued a buy rating and set a $135.00 price target on shares of GW Pharmaceuticals PLC in a report on Monday, June 27th. Finally, Piper Jaffray Cos. reissued a buy rating and set a $147.00 price target on shares of GW Pharmaceuticals PLC in a report on Sunday, June 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $138.83.

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 0.48% during midday trading on Friday, reaching $130.54. 142,393 shares of the company were exchanged. GW Pharmaceuticals PLC has a 52-week low of $35.83 and a 52-week high of $137.88. The firm’s 50 day moving average is $104.51 and its 200-day moving average is $90.78. The company’s market capitalization is $2.86 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($1.21) by $1.15. The firm earned $3.10 million during the quarter, compared to the consensus estimate of $3.63 million. GW Pharmaceuticals PLC had a negative net margin of 409.40% and a negative return on equity of 26.26%. The firm’s revenue was down 73.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.09) earnings per share. On average, equities analysts forecast that GW Pharmaceuticals PLC will post ($4.52) earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of GWPH. Advisory Services Network LLC increased its stake in GW Pharmaceuticals PLC by 1,109.2% in the third quarter. Advisory Services Network LLC now owns 786 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 721 shares during the last quarter. IFP Advisors Inc boosted its position in GW Pharmaceuticals PLC by 15.3% in the first quarter. IFP Advisors Inc now owns 1,759 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 234 shares during the period. Seven Eight Capital LLC boosted its position in GW Pharmaceuticals PLC by 216.7% in the first quarter. Seven Eight Capital LLC now owns 1,900 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 1,300 shares during the period. Rothschild Investment Corp IL acquired a new position in GW Pharmaceuticals PLC during the second quarter valued at $200,000. Finally, HighTower Advisors LLC acquired a new position in GW Pharmaceuticals PLC during the second quarter valued at $203,000. Hedge funds and other institutional investors own 68.71% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

5 Day Chart for NASDAQ:GWPH

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.